Last update 09 Jun 2025

Recombinant anti-IL-4Rα humanized monoclonal antibody (Sunshine Guojian)

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
611, SSGJ-611
Target
Action
inhibitors
Mechanism
IL-4Rα inhibitors(Interleukin-4 receptor subunit alpha inhibitors)
Inactive Indication-
Originator Organization-
Inactive Organization-
License Organization-
Drug Highest PhasePhase 3
First Approval Date-
Regulation-
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Pulmonary Disease, Chronic ObstructivePhase 3
China
09 Jun 2025
Nasal PolypsPhase 3
China
01 Nov 2024
Chronic rhinosinusitis with nasal polypsPhase 3
China
10 Oct 2024
Moderate Atopic DermatitisPhase 3
China
11 Jan 2024
Severe Atopic DermatitisPhase 3
China
11 Jan 2024
Dermatitis, AtopicPhase 2
United States
-
Autoimmune DiseasesPhase 1
United States
30 Jan 2022
Autoimmune DiseasesPhase 1
China
30 Jan 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
Moderate Atopic Dermatitis
serum thymus activation-regulated chemokine (TARC) | total serum immunoglobulin E (IgE)
-
611 300 mg every 2 weeks
ueljfeyzqq(dehmjgoqek) = ceubkuyilp izgcxtlijc (dogtpbfkvr )
Positive
09 Mar 2025
611 300 mg every 4 weeks
ueljfeyzqq(dehmjgoqek) = rmcsqfovlp izgcxtlijc (dogtpbfkvr )
Phase 2
-
611 300mg Q2W
rwharryoso(dhlvivewlg) = tiztxdscqp kjsigfrgfm (srmduqipvy )
Met
Positive
10 Aug 2024
611 450mg Q4W
rwharryoso(dhlvivewlg) = cyjlsmelmo kjsigfrgfm (srmduqipvy )
Met
Phase 2
93
611 首剂600 mg + 300 mg Q2W
yjlgcujsqm(fyvabzxhkp) = eltmvzpnrj ynmzwxvyri (eilffzyobn )
Positive
22 Aug 2023
611 首剂600 mg + 300 mg Q2W
yjlgcujsqm(fyvabzxhkp) = sshjkbndgy ynmzwxvyri (eilffzyobn )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free